vs
莫德纳（MRNA）与Ryman Hospitality Properties, Inc.（RHP）财务数据对比。点击上方公司名可切换其他公司
莫德纳的季度营收约是Ryman Hospitality Properties, Inc.的1.4倍（$1.0B vs $737.8M），Ryman Hospitality Properties, Inc.净利率更高（10.1% vs -19.7%，领先29.8%），Ryman Hospitality Properties, Inc.同比增速更快（13.9% vs -45.4%），Ryman Hospitality Properties, Inc.自由现金流更多（$58.5M vs $-880.0M），过去两年Ryman Hospitality Properties, Inc.的营收复合增速更高（18.2% vs -45.0%）
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
莱曼酒店地产是一家主营酒店、度假村、娱乐及媒体业务的企业，得名于旗下位于田纳西州纳什维尔的国家历史地标莱曼礼堂。公司历史可追溯至曾为俄克拉荷马出版公司子公司时期，1983年收购WSM公司后奠定现代业务基础，同时将知名演出IP大奥普里等核心资产纳入麾下。
MRNA vs RHP — 直观对比
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $737.8M |
| 净利润 | $-200.0M | $74.5M |
| 毛利率 | 79.6% | 41.4% |
| 营业利润率 | -25.6% | 19.4% |
| 净利率 | -19.7% | 10.1% |
| 营收同比 | -45.4% | 13.9% |
| 净利润同比 | -1638.5% | 3.0% |
| 每股收益（稀释后） | $-0.51 | $1.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $737.8M | ||
| Q3 25 | $1.0B | $592.5M | ||
| Q2 25 | — | $659.5M | ||
| Q1 25 | — | $587.3M | ||
| Q4 24 | $966.0M | $647.6M | ||
| Q3 24 | $1.9B | $550.0M | ||
| Q2 24 | — | $613.3M | ||
| Q1 24 | — | $528.3M |
| Q4 25 | — | $74.5M | ||
| Q3 25 | $-200.0M | $34.9M | ||
| Q2 25 | — | $71.8M | ||
| Q1 25 | — | $63.0M | ||
| Q4 24 | $-1.1B | $72.3M | ||
| Q3 24 | $13.0M | $59.0M | ||
| Q2 24 | — | $100.8M | ||
| Q1 24 | — | $42.8M |
| Q4 25 | — | 41.4% | ||
| Q3 25 | 79.6% | 40.9% | ||
| Q2 25 | — | 49.7% | ||
| Q1 25 | — | 44.4% | ||
| Q4 24 | 23.5% | 40.4% | ||
| Q3 24 | 72.4% | 43.1% | ||
| Q2 24 | — | 48.4% | ||
| Q1 24 | — | 41.5% |
| Q4 25 | — | 19.4% | ||
| Q3 25 | -25.6% | 15.0% | ||
| Q2 25 | — | 21.1% | ||
| Q1 25 | — | 19.8% | ||
| Q4 24 | -129.0% | 18.6% | ||
| Q3 24 | -3.8% | 19.3% | ||
| Q2 24 | — | 27.4% | ||
| Q1 24 | — | 18.2% |
| Q4 25 | — | 10.1% | ||
| Q3 25 | -19.7% | 5.9% | ||
| Q2 25 | — | 10.9% | ||
| Q1 25 | — | 10.7% | ||
| Q4 24 | -115.9% | 11.2% | ||
| Q3 24 | 0.7% | 10.7% | ||
| Q2 24 | — | 16.4% | ||
| Q1 24 | — | 8.1% |
| Q4 25 | — | $1.12 | ||
| Q3 25 | $-0.51 | $0.53 | ||
| Q2 25 | — | $1.12 | ||
| Q1 25 | — | $1.00 | ||
| Q4 24 | $-2.91 | $1.12 | ||
| Q3 24 | $0.03 | $0.94 | ||
| Q2 24 | — | $1.65 | ||
| Q1 24 | — | $0.67 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $471.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.3B | $750.2M |
| 总资产 | $12.1B | $6.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $471.4M | ||
| Q3 25 | $1.1B | $483.3M | ||
| Q2 25 | — | $420.6M | ||
| Q1 25 | — | $413.9M | ||
| Q4 24 | $1.9B | $477.7M | ||
| Q3 24 | $1.6B | $534.9M | ||
| Q2 24 | — | $498.4M | ||
| Q1 24 | — | $465.3M |
| Q4 25 | — | $750.2M | ||
| Q3 25 | $9.3B | $758.5M | ||
| Q2 25 | — | $800.4M | ||
| Q1 25 | — | $531.5M | ||
| Q4 24 | $10.9B | $549.0M | ||
| Q3 24 | $11.9B | $551.9M | ||
| Q2 24 | — | $562.6M | ||
| Q1 24 | — | $529.9M |
| Q4 25 | — | $6.2B | ||
| Q3 25 | $12.1B | $6.2B | ||
| Q2 25 | — | $6.1B | ||
| Q1 25 | — | $5.2B | ||
| Q4 24 | $14.1B | $5.2B | ||
| Q3 24 | $15.8B | $5.2B | ||
| Q2 24 | — | $5.1B | ||
| Q1 24 | — | $5.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-847.0M | $164.7M |
| 自由现金流经营现金流 - 资本支出 | $-880.0M | $58.5M |
| 自由现金流率自由现金流/营收 | -86.6% | 7.9% |
| 资本支出强度资本支出/营收 | 3.2% | 14.4% |
| 现金转化率经营现金流/净利润 | — | 2.21× |
| 过去12个月自由现金流最近4个季度 | $-1.9B | $232.4M |
8季度趋势，按日历期对齐
| Q4 25 | — | $164.7M | ||
| Q3 25 | $-847.0M | $205.2M | ||
| Q2 25 | — | $122.5M | ||
| Q1 25 | — | $98.2M | ||
| Q4 24 | $825.0M | $166.6M | ||
| Q3 24 | $-1.6B | $218.1M | ||
| Q2 24 | — | $184.3M | ||
| Q1 24 | — | $7.5M |
| Q4 25 | — | $58.5M | ||
| Q3 25 | $-880.0M | $135.4M | ||
| Q2 25 | — | $53.0M | ||
| Q1 25 | — | $-14.5M | ||
| Q4 24 | $303.0M | $76.0M | ||
| Q3 24 | $-1.7B | $85.7M | ||
| Q2 24 | — | $78.8M | ||
| Q1 24 | — | $-72.0M |
| Q4 25 | — | 7.9% | ||
| Q3 25 | -86.6% | 22.9% | ||
| Q2 25 | — | 8.0% | ||
| Q1 25 | — | -2.5% | ||
| Q4 24 | 31.4% | 11.7% | ||
| Q3 24 | -92.2% | 15.6% | ||
| Q2 24 | — | 12.9% | ||
| Q1 24 | — | -13.6% |
| Q4 25 | — | 14.4% | ||
| Q3 25 | 3.2% | 11.8% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | 54.0% | 14.0% | ||
| Q3 24 | 8.1% | 24.1% | ||
| Q2 24 | — | 17.2% | ||
| Q1 24 | — | 15.0% |
| Q4 25 | — | 2.21× | ||
| Q3 25 | — | 5.88× | ||
| Q2 25 | — | 1.71× | ||
| Q1 25 | — | 1.56× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | -120.46× | 3.70× | ||
| Q2 24 | — | 1.83× | ||
| Q1 24 | — | 0.17× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
RHP
| Hotel Other | $157.7M | 21% |
| Gaylord Opryland | $147.4M | 20% |
| Hotel Transient Rooms | $93.6M | 13% |
| Hotel Food And Beverage Outlets | $92.2M | 12% |
| Gaylord Palms | $88.2M | 12% |
| Jw Marriott Hill Country | $53.7M | 7% |
| Entertainment Admissions And Ticketing | $43.1M | 6% |
| Entertainment Food And Beverage | $38.1M | 5% |
| Entertainment Retail And Other | $28.3M | 4% |
| Ac Hotel | $2.4M | 0% |
